The vaccine elicited an immune system response in 94% of participants who completed the so-called phase 1 clinical trial.
–
Lhe biotech company Inovio announced Tuesday encouraging preliminary results for its vaccine project against the new coronavirus, administered on 40 volunteers in the United States.
According to a company press release, the vaccine caused an immune system response in 94% of the participants who followed the so-called phase 1 clinical trial, that is to say with two injections four weeks apart.
–
The Inovio vaccine, called INO-4800, involves injecting a DNA genetic code into the person’s body to trigger a specific immune response against the SARS-CoV-2 coronavirus.
“No need to be frozen”
The vaccine is injected under the skin by a needle, then it is activated by a device resembling a toothbrush, which delivers an electric mini-pulse, of a fraction of a second, allowing the DNA to penetrate the cells of the body and fulfill its mission there.
Inovio, already funded by the US Department of Defense and the NGO Cepi, also announces that it has been selected by President Donald Trump’s program to try to produce hundreds of millions of doses of vaccine by January 2021.
The company’s vaccine is the only DNA vaccine “stable at room temperature for more than a year”, and “which does not need to be frozen for transport or to be stored for years,” said the CEO. from Inovio, Joseph Kim.
–
– .
